Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01137747 · ClinicalTrials.gov registry record · Phase 1
Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01137747 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 18 participants.
The verdict
NCT01137747, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study is to test escalating doses of carfilzomib in patients with relapsed acute myeloid and acute lymphoblastic leukemia.
Interventions
- DRUG Carfilzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-10 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01137747
The ClinicalTrials.gov registry entry for NCT01137747 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Carfilzomib is the first listed.
NCT01137747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01137747 about?
NCT01137747 is a clinical study titled "Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia". This study is to test escalating doses of carfilzomib in patients with relapsed acute myeloid and acute lymphoblastic leukemia.
What is the current status of trial NCT01137747?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-10. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01137747?
The interventions under investigation include: Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT01137747?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.